Literature DB >> 33794075

Metabolic rewiring: a new master of Th17 cell plasticity and heterogeneity.

Gina Papadopoulou1,2, Georgina Xanthou1.   

Abstract

T helper type 17 (Th17) cells are characterized by inherent plasticity and heterogeneity displaying both pathogenic and tissue-protective functions. Emerging evidence has illuminated a pivotal role for metabolic reprogramming in shaping Th17 cell fate determination. Metabolic responses are regulated by a constellation of factors and environmental triggers, including cytokines, nutrients, oxygen levels, and metabolites. Dysregulation of metabolic pathways not only influences Th17 cell plasticity and effector function but also affects the outcome of Th17-linked autoimmune, inflammatory, and antitumor responses. Understanding the molecular mechanisms underpinning metabolic reprogramming can allow the enhancement of protective Th17 cell-mediated responses during infections and cancer, concomitant with the suppression of detrimental Th17 processes during autoimmune and inflammatory diseases. In the present review, we describe major metabolic pathways underlying the differentiation of Th17 cells and their crosstalk with intracellular signaling mediators, we discuss how metabolic reprogramming affects Th17 cell plasticity and functions, and, finally, we outline current advances in the exploitation of metabolic checkpoints for the development of novel therapeutic interventions for the management of tissue inflammation, autoimmune disorders, and cancer.
© 2021 Federation of European Biochemical Societies.

Entities:  

Keywords:  Th17 cells; autoimmunity; cytokines; enzymes; epigenome; immunometabolism; inflammation

Mesh:

Year:  2021        PMID: 33794075     DOI: 10.1111/febs.15853

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  2 in total

1.  Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease.

Authors:  Ju Mi Lee; Jiyun Park; Steven G Reed; Rhea N Coler; Jung Joo Hong; Lee-Han Kim; Wonsik Lee; Kee Woong Kwon; Sung Jae Shin
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

2.  Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR-Driven Lung Cancer.

Authors:  Mofei Huang; Donghai Xiong; Jing Pan; Qi Zhang; Shizuko Sei; Robert H Shoemaker; Ronald A Lubet; Luis M Montuenga; Yian Wang; Barbara S Slusher; Ming You
Journal:  Adv Sci (Weinh)       Date:  2022-07-21       Impact factor: 17.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.